Results 101 to 110 of about 8,127 (167)

First-Line Palbociclib/Letrozole Versus Ribociclib/Letrozole in Postmenopausal HR-Positive/HER2-Negative Metastatic Breast Cancer: A Retrospective Real-World Study and an Exploratory Composite Clinical-Inflammatory Risk Score. [PDF]

Medicina (Kaunas)
Tohumcuoğlu M, Yetişir AE, Cinkara ZU, Türker M, Düşgün A, Mirili C, Tazeoğlu D, Köşeci T, Oğul A, Büyükşimşek M.   +9 more
europepmc   +1 more source

A Systematic Literature Review of the Effectiveness of CDK 4/6 Inhibitors for First-Line Treatment of HR+/HER2- Advanced/Metastatic Breast Cancer: A Comparison of Real-World Evidence. [PDF]

Cancers (Basel)
Pluard T, Grinda T, Dienstmann R, Thill M, Korytowsky B, Chen C, Portuhay S, Salvo-Halloran EM, Samjoo IA, Harbeck N.   +9 more
europepmc   +1 more source

Real-world postprogression outcomes after first-line treatment with ribociclib plus aromatase inhibitor versus aromatase inhibitor alone in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in the United States of America. [PDF]

ESMO Open
Hart L, Rugo HS, Sharma P, Sammons S, Gadi VK, Mavros P, Kaur M, Boualam N, Keane C, Sopher G, Pathak P, Tarantino P.   +11 more
europepmc   +1 more source

Quantitative Pharmacology Justifying Ribociclib Dose in Early Breast Cancer. [PDF]

Clin Pharmacokinet
Ji Y, Wang C, Combes FP, Ho YY, Fasching PA, Untch M, Zarate JP, Crown J.   +7 more
europepmc   +1 more source

Comparative safety signal prioritization of CDK4/6 inhibitors in breast cancer: a FAERS pharmacovigilance, machine learning, and clinical contextualization study. [PDF]

Front Pharmacol
Fan L, Liu S, Tang Y, Han X, Zhang Z, Su C, Sui Z, Zhao W.   +7 more
europepmc   +1 more source

Gastrointestinal toxicity associated with cyclin-dependent kinase 4/6 inhibitors in breast cancer patients: insights from a real-world pharmacovigilance analysis. [PDF]

Front Med (Lausanne)
Lu M, Yuan L, Liu J, Dou Y, Cui J.
europepmc   +1 more source

Adjuvant CDK4/6 inhibitors in early-stage breast cancer: Clinical evidence and considerations for risk stratification and treatment selection. [PDF]

Cancer
Williams AD, Weiss A.
europepmc   +1 more source

<i>CDK4/6</i> Inhibitors in Breast Cancer: Clinical Applications, Translational Insights, and Future Directions. [PDF]

Cancers (Basel)
Guan M, Hao H.
europepmc   +1 more source

Age, Age-Related Comorbidities and Survival in Palbociclib, Ribociclib and Abemaciclib Users With Advanced Breast Cancer: A Nation-Wide Retrospective Cohort Study. [PDF]

Pharmacoepidemiol Drug Saf
Rajamaki B, Tenhunen O, Pylkkänen L, Vo T, Paakinaho A, Turpeinen M, Hartikainen S, Tolppanen AM.   +7 more
europepmc   +1 more source

Comparison of survival outcomes for people with HR+/HER2- metastatic breast cancer who received palbociclib, ribociclib, or abemaciclib with an aromatase inhibitor: a plain language summary. [PDF]

Future Oncol
Rugo HS, Layman RM, Lynce F, Liu X, Li B, McRoy L, Cohen AB, Estevez M, Curigliano G, Brufsky A.   +9 more
europepmc   +1 more source